neoplasms/protease

FIELD This application relates to novel variant proaerolysin (PA) proteins and methods of their use to treat localized and metastatic prostate cancer. BACKGROUND One of every three cancers diagnosed in American males is of prostatic origin, making prostate cancer the most commonly diagnosed

FIELD This application relates to novel variant proaerolysin (PA) proteins and methods of their use to treat localized and metastatic prostate cancer. BACKGROUND One of every three cancers diagnosed in American males is of prostatic origin, making prostate cancer the most commonly diagnosed

FIELD This application relates to novel variant proaerolysin (PA) proteins and methods of their use to treat localized and metastatic prostate cancer. BACKGROUND One of every three cancers diagnosed in American males is of prostatic origin, making prostate cancer the most commonly diagnosed

FIELD OF THE INVENTION The described invention generally relates to ovarian cancer. BACKGROUND Ovarian Cancer Ovarian cancer ranks as the fifth most common cancer in women and has the highest mortality rate among gynecologic malignancies (Suh K S, Park S W, Castro A, Patel H, Blake P, Liang M, et

BACKGROUND OF THE INVENTION 1. Field of the Invention This invention relates to an anti-tumor agent containing protease originating from microorganisms as an effective component, to an anti-tumor agent containing chemically modified protease originating from microorganisms as an effective component,

BACKGROUND OF THE INVENTION 1. Field of Invention This invention relates to serine protease inhibitor Kazal (SPIK/SPINK/PSTI) and more specifically, its inhibitors and the use of inhibitors of SPIK as anti-cancer agents and anti-viral agents such as hepatitis B and C virus (HBV and HCV). 2.

FIELD OF THE INVENTION This invention pertains to methods and composition that find use in diagnostic, prognostic and characterization of neoplasia samples based on the ability of a neoplasia sample to cleave a MTS molecule of the present invention. BACKGROUND OF THE INVENTION Introduction Cell

FIELD OF THE INVENTION The present invention provides Methyl- (or Mutant-) Differential Display (MDD) methods and nucleic acid probes for detecting mutations and/or the methylation patterns of nucleic acids. Genes are frequently not methylated in the cells where they are expressed but are methylated

BACKGROUND OF THE INVENTION 1. Field of the Invention The invention relates generally to the prostate and specifically to a novel complex of hK2 and PI-6 formed in the prostate, and methods of using the novel complex. 2. Description of the Prior Art Throughout this application, various references

BACKGROUND OF THE INVENTION 1. Field of the Invention The invention relates generally to the prostate and specifically to a novel complex of hK2 and PI-6 formed in the prostate, and methods of using the novel complex and its constituents. 2. Description of the Prior Art Throughout this application,

FIELD OF THE INVENTION The invention relates to an enzyme, arginine deiminase. In particular, it relates to a unique arginine deiminase isolated from mycoplasmas. More particularly, the invention is directed to a mycoplasmal proteinase K resistant arginine deiminase and to a method of preparing

FIELD OF THE INVENTION The invention relates to proteins useful as therapeutics against cancer, viral infections, parasitic and fungal infections. The proteins contain A and B chains of a ricin-like toxin linked by a linker sequence that is specifically cleaved and activated by proteases specific to

FIELD OF THE INVENTION The present invention relates generally to the field of medicine, and relates specifically to angiogenesis and metastasis of cancer tissues. Specifically the invention relates to the use of antagonists of the serine integral membrane protease, dipeptidyl peptidase IV (DPPIV

TECHNICAL FIELD The present invention relates to cancer cell migration and cancer cell invasion inhibitors. More specifically, the present invention relates to a PAR1 antibody inhibiting a cell migration activity and a cell invasion activity induced by MMP1 as well as a medicinal composition

CROSS REFERENCE TO RELATED APPLICATION This application is a National Stage of International Application No. PCT/KR2011/009914 filed Dec. 21, 2011, claiming priority based on Korean Patent Application No. 10-2010-0132955 filed Dec. 23, 2010, the contents of all of which are incorporated herein by